Get started
Context Therapeutics Inc.Context Therapeutics Inc.Context Therapeutics Inc.

Context Therapeutics Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

CNTX chart


Full chart

CNTX upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪74.81 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.5250 USD
Net income (FY)
‪−26.73 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪52.33 M‬
Beta (1Y)
1.20

Employees


Employees (FY)
12
Change (1Y)
+7 +140.00%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−2.23 M‬ USD

About Context Therapeutics Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Martin A. Lehr
Website
contexttherapeutics.com
Headquarters
Philadelphia
Founded
2015
FIGI
BBG011YW6H86
Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The firm's robust clinical program for candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. Its ONA-XR is a novel, first-in-class small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women?s cancers. The company was founded by Martin Lehr and Felix Kim in April 2015 and is headquartered in Philadelphia, PA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

CNTX news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as CNTX.

Frequently Asked Questions


The current price of CNTX is 0.9437 USD — it has increased by 13.05% in the past 24 hours. Watch Context Therapeutics Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Context Therapeutics Inc. stocks are traded under the ticker CNTX.
CNTX stock has risen by 8.37% compared to the previous week, the month change is a 22.44% rise, over the last year Context Therapeutics Inc. has showed a −34.91% decrease.
We've gathered analysts' opinions on Context Therapeutics Inc. future price: according to them, CNTX price has a max estimate of 9.00 USD and a min estimate of 4.00 USD. Watch CNTX chart and read a more detailed Context Therapeutics Inc. stock forecast: see what analysts think of Context Therapeutics Inc. and suggest that you do with its stocks.
CNTX reached its all-time high on Dec 1, 2021 with the price of 10.8700 USD, and its all-time low was 0.4700 USD and was reached on May 15, 2023. View more price dynamics on CNTX chart.
See other stocks reaching their highest and lowest prices.
CNTX stock is 12.36% volatile and has beta coefficient of 1.20. Track Context Therapeutics Inc. stock price on the chart and check out the list of the most volatile stocks — is Context Therapeutics Inc. there?
Today Context Therapeutics Inc. has the market capitalization of ‪84.57 M‬, it has increased by 8.08% over the last week.
Yes, you can track Context Therapeutics Inc. financials in yearly and quarterly reports right on TradingView.
Context Therapeutics Inc. is going to release the next earnings report on May 7, 2025. Keep track of upcoming events with our Earnings Calendar.
CNTX earnings for the last quarter are −0.03 USD per share, whereas the estimation was −0.092 USD resulting in a 67.39% surprise. The estimated earnings for the next quarter are −0.058 USD per share. See more details about Context Therapeutics Inc. earnings.
Context Therapeutics Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
CNTX net income for the last quarter is ‪−3.34 M‬ USD, while the quarter before that showed ‪−17.46 M‬ USD of net income which accounts for 80.85% change. Track more Context Therapeutics Inc. financial stats to get the full picture.
No, CNTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 23, 2025, the company has 12 employees. See our rating of the largest employees — is Context Therapeutics Inc. on this list?
Like other stocks, CNTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Context Therapeutics Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Context Therapeutics Inc. technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Context Therapeutics Inc. stock shows the sell signal. See more of Context Therapeutics Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.